bpc-157 clinicaltrials.gov | C62H98N16O22 | CID 9941957 BPC-157 vs TB-500: research summary
Description
Another aspect to consider is the formulation, to design and tailor appropriate IN drug formulations
It does not recommend dosing for humans or animals
- Lithium: because it reduces the renal clearance and increases lithium levels in plasma which increases the risk of lithium toxicity
10.1155/2015/512618 89 MaieseK
BPC-157 is a pentadecapeptide consisting of 15 amino acids derived from a biologically active region of a gastric protein sequence, while TB-500 corresponds to a synthetic fragment of thymosin beta-4 that retains actin-binding regulatory activity observed in the native protein
